Most Read Articles
Pearl Toh, 08 Jun 2016
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Roshini Claire Anthony, 19 Sep 2016

Benralizumab reduced asthma exacerbations and improved lung function in patients with severe, eosinophilic asthma, according to results of the SIROCCO* and CALIMA** trials which were presented at the European Respiratory Society (ERS) International Congress 2016 held in London, UK.

01 Apr 2016
New drug applications approved by US FDA as of 16 - 31 Mar 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
16 Apr 2015
New drug applications approved by US FDA as of 1 – 15 April 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The Role of Modern Second-generation Antihistamines in Allergic Rhinitis

25 Jul 2017
Allergic rhinitis (AR) is a common global health problem that poses a significant impact on the quality of life and productivity of affected patients. At the Ear, Nose and Throat (ENT) Summit 2017 held recently at  Hilton Sentral, Kuala Lumpur, Malaysia, Associate Professor Marysia P Tiongco-Recto was invited by A. Menarini to deliver a lecture on the potential of modern second-generation antihistamines, particularly bilastine (Bilaxten®) in the management of AR.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 08 Jun 2016
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Roshini Claire Anthony, 19 Sep 2016

Benralizumab reduced asthma exacerbations and improved lung function in patients with severe, eosinophilic asthma, according to results of the SIROCCO* and CALIMA** trials which were presented at the European Respiratory Society (ERS) International Congress 2016 held in London, UK.

01 Apr 2016
New drug applications approved by US FDA as of 16 - 31 Mar 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
16 Apr 2015
New drug applications approved by US FDA as of 1 – 15 April 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.